Pharma News

At the pinnacle of the online era, the Indian Pharmacopoeia Commission (IPC) is set to digitize Indian Pharmacopoeia (IP) to increase its coverage.

IPC has invited tender on Gem Portal (Government E Marketplace) from eligible and qualified IT firms related to online portal Development, application development, data digitalization or online content management etc for the project.

FDA lays aside Lilly's bebtelovimab in the U.S. for emergency use treatment of mild-to-moderate COVID-19 in adults and pediatric patients. Over the last several months, prevalence of COVID variant sublineages vary by state, region and even country, and can change rapidly.

Lilly said that it agrees with the FDA that it is not medically appropriate, at this time, to treat high-risk patients with mild-to-moderate COVID-19 with bebtelovimab in the US.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

Mrs. Archna Mudgal who was serving as registrar cum secretary has taken voluntary retirement from PCI, notified by Pharmacy council of India. And Mr Anil Mittal, Deputy Secretary has taken charge as Registrar-cum-Secretary.

A notification published on Pharmacy Council of India (PCI) portal said, "Due to Voluntary Retirement taken by Smt. Archna Mudgal, Registrar-cum-Secretary, PCI, Shri Anil Mittal, Deputy Secretary will hold the charge of Registrar-cum-Secretary."

The Singapore based subsidiary of Gland Pharma has acquired Europe based Cenexi Group which is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of pharmaceutical products with expertise in sterile liquid and lyophilized fill- finished drugs, including capabilities on oncology and complex products.

The Gland Pharma entered into a put option agreement to acquire 100 percent of Cenexi Group for an Equity Value not exceeding Euro 120 Mn (Enterprise Value of Euro 230 Mn).

Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc for a cash price of 10 USD per share, reflecting an enterprise value of approximately 615 million USD.

AstraZeneca announces the sale of its West Chester site in Ohio, US, to National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines.

Roche voluntarily withdraws the U.S. indication of Tecentriq (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma, a bladder cancer.

An estimated 81,000 cases of bladder cancer will be diagnosed in the United States in 2022. Urothelial carcinoma, which develops in the cells of the bladder lining, is the most common type of bladder cancer, accounting for about 90% of all cases. In total, 30% of cases are considered advanced based on muscle-invasive or metastatic disease.

Temporal lobe epilepsy (TLE) is one of the most common types of epilepsy worldwide. Although symptomatic medications are available, one-third of TLE patients remain unresponsive to current treatment, so new drug targets are critically needed. A research team co-led by a City University of Hong Kong (CityU) neuroscientist recently identified and developed a new drug candidate that has potential for effectively treating TLE by suppressing neuroinflammation.